Hong Kong Researchers Present Preclinical Data on GLP-1 Agonists in Stroke Models Combined with Thrombectomy

Chinese University of Hong Kong scientists stated on Thursday that Chinese University of Hong Kong scientists have presented preclinical findings suggesting that GLP-1 receptor agonists may have neuroprotective effects in ischemic stroke models when combined with mechanical thrombectomy.

Administering a GLP-1 injection before and after a thrombectomy produced measurable improvements in neurological scores in preclinical models, equivalent to up to a 20% gain on the scales used. if they missed the window for an intravenous thrombolysis, the scientists said.

Ischemic strokes account for 80 per cent of all stroke cases globally and are caused by the obstruction of blood vessels supplying blood to the brain.

Dr Ko Ho, director of the Gerald Choa Neuroscience Institute and an associate professor of CU Medicine, said the team made the discovery while pursuing effective interventions targeting ageing-related biological changes. The scientists made the statement on Thursday, according to @SCMPNews reported. “Our team began prioritising the GLP-1 signalling pathway about seven or eight years ago.

GLP-1 is a ‘superstar’ pathway in biological, medical and pharmaceutical fields, primarily due to its success in treating type 2 diabetes and obesity,” Dr Ko Ho said. GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, are a class of prescription medications that mimic a natural gut hormone to regulate blood sugar and suppress appetite.

Dr Ko Ho said clinical data previously indicated that beyond lowering blood sugar and reducing weight, GLP-1 appeared to offer additional benefits that could not be explained at that time.

Dr Ko Ho said the team asked whether one of the additional benefits of GLP-1 could be anti-ageing, and that was the basis of their research. The article was published on 14 May 2026. The findings centre on patients who arrive too late for standard clot-busting intravenous thrombolysis but remain eligible for mechanical thrombectomy.

By injecting the GLP-1 drug immediately before and after the catheter-based clot removal, the CUHK team observed measurable gains in neurological scores in preclinical models, pointing to a protective effect on brain tissue during the critical reperfusion phase.

Dr Ko Ho framed the work as part of a broader hunt for therapies that counter the biological toll of ageing on the brain. The decision to focus on the GLP-1 pathway, taken seven or eight years ago, stemmed from its already established successes against type 2 diabetes and obesity, successes that hinted at wider metabolic and cellular repair mechanisms.

Clinical observations had long suggested GLP-1 drugs delivered benefits unrelated to glucose control or weight loss alone. Those unexplained improvements, Dr Ko Ho said, prompted the laboratory to test whether the pathway might slow or mitigate age-related decline in neural resilience following a major vascular event.

The research adds a potential new dimension to a class of medicines that have transformed treatment of metabolic disease.

While the CUHK team stopped short of announcing human trial results, its Thursday statement positions the neuroprotective angle as a logical extension of the drugs’ existing therapeutic profile.